Teleflex (TFX) Scheduled to Post Earnings on Thursday

Teleflex (NYSE:TFX) is scheduled to be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Teleflex to post earnings of $3.07 per share for the quarter. Teleflex has set its FY 2024 guidance at 13.550-13.950 EPS and its FY24 guidance at $13.55-$13.95 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, beating analysts’ consensus estimates of $3.26 by $0.12. Teleflex had a net margin of 11.98% and a return on equity of 14.98%. The firm had revenue of $773.90 million for the quarter, compared to the consensus estimate of $769.01 million. During the same period in the prior year, the firm posted $3.52 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, analysts expect Teleflex to post $14 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Teleflex Trading Up 0.0 %

NYSE TFX opened at $211.17 on Thursday. Teleflex has a 12 month low of $177.63 and a 12 month high of $276.43. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.32 and a quick ratio of 1.29. The company has a market capitalization of $9.95 billion, a price-to-earnings ratio of 28.04, a price-to-earnings-growth ratio of 1.98 and a beta of 1.11. The company’s fifty day moving average price is $223.09 and its two-hundred day moving average price is $225.66.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were given a $0.34 dividend. The ex-dividend date was Thursday, February 29th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.64%. Teleflex’s payout ratio is currently 18.06%.

Analyst Ratings Changes

TFX has been the topic of a number of recent research reports. JMP Securities restated a “market outperform” rating and issued a $285.00 price target on shares of Teleflex in a research report on Friday, February 23rd. Royal Bank of Canada reduced their price target on shares of Teleflex from $272.00 to $265.00 and set an “outperform” rating on the stock in a research report on Friday, February 23rd. StockNews.com downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Finally, Truist Financial reduced their price target on shares of Teleflex from $270.00 to $265.00 and set a “hold” rating on the stock in a research report on Friday, February 23rd. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Teleflex presently has an average rating of “Moderate Buy” and an average target price of $267.50.

Insider Buying and Selling

In related news, VP Cameron P. Hicks sold 7,401 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total value of $1,665,225.00. Following the sale, the vice president now owns 10,050 shares of the company’s stock, valued at approximately $2,261,250. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.43% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.